Soluble mediators of inflammation during tumor development

被引:88
作者
Robinson, SC [1 ]
Coussens, LM
机构
[1] Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA
来源
ADVANCES IN CANCER RESEARCH, VOL 93 | 2005年 / 93卷
关键词
D O I
10.1016/S0065-230X(05)93005-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tissues maintain homeostasis by monitoring and responding to varied physical interactions between cells and their microenvironment. In situations where acute tissue damage occurs, such as wounding, pathogenic assault, or toxic exposure, regulatory circuits that monitor tissue homeostasis are rapidly engaged to initiate tissue repair by regulating cell polarity, proliferation and death, matrix metabolism, inflammation, and vascular and lymphatic function. The critical feature of regulating these acute responses is the innate ability to discriminate between homeostatic versus damaged tissue states and engage or disengage regulatory machinery as appropriate; thus, a major distinction between acute versus chronic disease is the altered ability to appropriately activate and/ or inactivate reparative regulatory programs. Since cancer is a chronic disease characterized by altered cell polarity, enhanced cell survival, inflammation, increased matrix metabolism, and enhanced vascular and lymphatic function, considerable attention is now focused on understanding the cellular and molecular mechanisms regulating these responsive pathways. Since chemoattractant cytokines are important mediators of leukocyte recruitment following acute tissue stress, and demonstrate altered characteristics of expression and activation in chronically inflamed tissue, they have been implicated as key regulators of inflammation and angiogenesis during cancer development. This chapter focuses on the clinical and experimental data implicating proinflammatory cytokines and chemokines as important potentiators of carcinogenesis. (c) 2005 Elsevier Inc.
引用
收藏
页码:159 / 187
页数:29
相关论文
共 196 条
[61]   Mast cells correlate with angiogenesis and poor outcome in stage I lung adenocarcinoma [J].
Imada, A ;
Shijubo, N ;
Kojima, H ;
Abe, S .
EUROPEAN RESPIRATORY JOURNAL, 2000, 15 (06) :1087-1093
[62]  
Ishigami S, 2003, ANTICANCER RES, V23, P4079
[63]  
Janeway C, 2001, IMMUNOBIOLOGY
[64]   EXPRESSION OF ADHESION MOLECULES AND CHEMOTACTIC CYTOKINES IN CULTURED HUMAN MESOTHELIAL CELLS [J].
JONJIC, N ;
PERI, G ;
BERNASCONI, S ;
SCIACCA, FL ;
COLOTTA, F ;
PELICCI, P ;
LANFRANCONE, L ;
MANTOVANI, A .
JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 176 (04) :1165-1174
[65]  
KAMBAYASHI T, 1995, J IMMUNOL, V154, P3383
[66]   Depletion of CXCR2 inhibits tumor growth and angiogenesis in a murine model of lung cancer [J].
Keane, MP ;
Belperio, JA ;
Xue, YY ;
Burdick, MD ;
Strieter, RM .
JOURNAL OF IMMUNOLOGY, 2004, 172 (05) :2853-2860
[67]  
Koki Alane T, 2002, Cancer Control, V9, P28
[68]   Role of TNF/TNFR in autoimmunity: specific TNF receptor blockade may be advantageous to anti-TNF treatments [J].
Kollias, G ;
Kontoyiannis, D .
CYTOKINE & GROWTH FACTOR REVIEWS, 2002, 13 (4-5) :315-321
[69]   Introduction: The complexities of leukocyte recruitment [J].
Kubes, P .
SEMINARS IN IMMUNOLOGY, 2002, 14 (02) :65-72
[70]   Infections as a major preventable cause of human cancer [J].
Kuper, H ;
Adami, HO ;
Trichopoulos, D .
JOURNAL OF INTERNAL MEDICINE, 2000, 248 (03) :171-183